MA49809A1 - Composés utilisés comme inhibiteurs de kinase - Google Patents
Composés utilisés comme inhibiteurs de kinaseInfo
- Publication number
- MA49809A1 MA49809A1 MA49809A MA49809A MA49809A1 MA 49809 A1 MA49809 A1 MA 49809A1 MA 49809 A MA49809 A MA 49809A MA 49809 A MA49809 A MA 49809A MA 49809 A1 MA49809 A1 MA 49809A1
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitors
- compounds used
- tyrosine kinase
- compounds
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 2
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
La présente invention concerne de nouveaux composés. Les composés selon l'invention sont des inhibiteurs de tyrosine kinase. De manière spécifique, les composés selon l'invention sont utilisés comme inhibiteurs de la tyrosine kinase de bruton (btk). L'invention concerne également l'utilisation de ces composés pour le traitement d'affections pouvant être traitées en inhibant la tyrosine kinase de bruton, par exemple le cancer, le lymphome, la leucémie et les maladies immunologiques.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1522245.8A GB201522245D0 (en) | 2015-12-16 | 2015-12-16 | Compounds useful as kinase inhibitors |
GBGB1613945.3A GB201613945D0 (en) | 2016-08-15 | 2016-08-15 | Compounds useful as kinase inhibitors |
PCT/GB2016/053968 WO2017103611A1 (fr) | 2015-12-16 | 2016-12-16 | Composés utilisés comme inhibiteurs de kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49809A1 true MA49809A1 (fr) | 2021-08-31 |
Family
ID=57590725
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49809A MA49809A1 (fr) | 2015-12-16 | 2016-12-16 | Composés utilisés comme inhibiteurs de kinase |
MA055064A MA55064A (fr) | 2015-12-16 | 2016-12-16 | Composés utilisés comme inhibiteurs de kinase |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055064A MA55064A (fr) | 2015-12-16 | 2016-12-16 | Composés utilisés comme inhibiteurs de kinase |
Country Status (35)
Country | Link |
---|---|
US (7) | US10695323B2 (fr) |
EP (2) | EP3390395B1 (fr) |
JP (3) | JP6731483B2 (fr) |
KR (2) | KR102215792B1 (fr) |
CN (9) | CN114573510A (fr) |
AU (4) | AU2016373530B2 (fr) |
CA (1) | CA3008488C (fr) |
CL (1) | CL2018001591A1 (fr) |
CO (1) | CO2018006164A2 (fr) |
CR (1) | CR20180367A (fr) |
CY (1) | CY1123561T1 (fr) |
DK (1) | DK3390395T3 (fr) |
EA (1) | EA035132B1 (fr) |
ES (1) | ES2828431T3 (fr) |
FI (1) | FIC20240004I1 (fr) |
HK (1) | HK1263254A1 (fr) |
HR (1) | HRP20201835T1 (fr) |
HU (2) | HUE051921T2 (fr) |
IL (4) | IL285976B2 (fr) |
LT (1) | LT3390395T (fr) |
MA (2) | MA49809A1 (fr) |
MD (1) | MD3390395T2 (fr) |
MX (2) | MX2018007267A (fr) |
NL (1) | NL301262I2 (fr) |
NZ (1) | NZ743553A (fr) |
PE (3) | PE20220507A1 (fr) |
PH (1) | PH12018501268A1 (fr) |
PT (1) | PT3390395T (fr) |
RS (1) | RS60982B1 (fr) |
SG (2) | SG11201805044WA (fr) |
SI (1) | SI3390395T1 (fr) |
TN (1) | TN2018000213A1 (fr) |
UA (2) | UA127863C2 (fr) |
WO (1) | WO2017103611A1 (fr) |
ZA (4) | ZA201804137B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
CN114685516A (zh) | 2015-09-16 | 2022-07-01 | 洛克索肿瘤学股份有限公司 | 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物 |
EP3390395B1 (fr) | 2015-12-16 | 2020-09-09 | Loxo Oncology, Inc. | Composés utilisés comme inhibiteurs de kinase |
GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
KR20210028144A (ko) * | 2018-04-06 | 2021-03-11 | 블랙 벨트 티엑스 리미티드 | Atf6 저해제 및 그의 용도 |
WO2019220962A1 (fr) * | 2018-05-18 | 2019-11-21 | 富士フイルム株式会社 | Procédé de production d'un composé 3-difluorométhylpyrazole, procédé de production d'un composé d'acide 3-difluorométhylpyrazole-4-carboxylique, et composé de pyrazolidine |
CA3108065A1 (fr) * | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Dispersions sechees par pulverisation, formulations et polymorphies de (s)-5-amino-3-(4-((5 fluoro-2-methoxybenzamido)methyl)phenyl)(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
WO2021028645A1 (fr) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
US20220273593A1 (en) * | 2019-09-19 | 2022-09-01 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Compounds and compositions for treating kidney disease |
CN110724135B (zh) * | 2019-11-18 | 2023-04-28 | 上海医药工业研究院有限公司 | 一种艾拉普林中间体及其制备方法 |
CA3160417A1 (fr) * | 2019-12-06 | 2021-06-10 | Loxo Oncology, Inc. | Dosage d'un inhibiteur de la tyrosine kinase de bruton |
WO2021180107A1 (fr) * | 2020-03-12 | 2021-09-16 | Fochon Pharmaceuticals, Ltd. | Composés utiles en tant qu'inhibiteurs de kinase |
TWI809489B (zh) | 2020-09-10 | 2023-07-21 | 美商絡速藥業公司 | 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體 |
CN112386597B (zh) * | 2020-10-15 | 2022-03-15 | 天津济坤医药科技有限公司 | 泽布替尼在制备治疗肺纤维化疾病药物中的应用 |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2022228302A1 (fr) * | 2021-04-25 | 2022-11-03 | Bionova Pharmaceuticals (Shanghai) Limited | Composés carboxamides hétéroaromatiques et leur utilisation |
WO2022240920A1 (fr) | 2021-05-14 | 2022-11-17 | Loxo Oncology, Inc. | Formes cocristallines d'un inhibiteur de la tyrosine kinase de bruton |
KR20240029070A (ko) * | 2021-07-01 | 2024-03-05 | 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 | 브루톤 티로신 키나아제, 이의 돌연변이체 분해제, 조성물 및 응용 |
CN115611810A (zh) * | 2021-07-16 | 2023-01-17 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
WO2023110970A1 (fr) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Inhibiteurs macrocycliques de btk |
WO2023143355A1 (fr) * | 2022-01-28 | 2023-08-03 | Hansoh Bio Llc | Dérivé d'amide d'azacycle, ses procédés de préparation et ses utilisations médicinales |
WO2023174397A1 (fr) * | 2022-03-18 | 2023-09-21 | Insilico Medicine Ip Limited | Inhibiteurs de kinase inhibitrice de cdc2 spécifique de la tyrosine et de la thréonine associés à une membrane de pyrazole (pkmyt1) et leurs utilisations |
CN115894376A (zh) * | 2022-12-15 | 2023-04-04 | 南京雷正医药科技有限公司 | 一种芳香族酰胺类化合物、药物组合物及其用途 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1212327T3 (da) | 1999-09-17 | 2003-12-15 | Abbott Gmbh & Co Kg | Pyrazolopyrimidiner som terapeutiske midler |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
US6291504B1 (en) * | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
US20030225098A1 (en) | 2002-03-21 | 2003-12-04 | Hirst Gavin C. | Kinase inhibitors |
KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
EP2068869A4 (fr) * | 2006-10-06 | 2011-05-25 | Abbott Lab | Nouveaux imidazothiazoles et imidazoxazoles |
CA2668286C (fr) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Sonde d'activite de la tyrosine kinase de bruton et son procede d'utilisation |
CA2874756C (fr) | 2007-03-28 | 2018-05-29 | Pharmacyclics, Inc. | Inhibiteurs de la tyrosine kinase de bruton |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
KR20110025224A (ko) | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
ES2660418T3 (es) | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
WO2010010154A1 (fr) * | 2008-07-24 | 2010-01-28 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles utilisés comme inhibiteurs de protéine kinase |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
CN107021951B (zh) * | 2010-06-30 | 2020-10-20 | 赛克里翁治疗有限公司 | sGC刺激物 |
PL2710007T3 (pl) | 2011-05-17 | 2020-06-01 | The Regents Of The University Of California | Inhibitory kinazy |
BR112013028846B1 (pt) | 2011-05-17 | 2021-12-07 | Principia Biopharma Inc | Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, processo de preparação, intermediários e composição farmacêutica |
KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
EP2548877A1 (fr) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
WO2014022569A1 (fr) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Traitement de la sécheresse oculaire |
EP2882741B1 (fr) * | 2012-08-10 | 2018-10-24 | Boehringer Ingelheim International GmbH | Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk) |
GB201214750D0 (en) * | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
US20150291554A1 (en) * | 2012-11-02 | 2015-10-15 | Pfizer Inc. | Bruton's Tyrosine Kinase Inhibitors |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
SG11201602070TA (en) * | 2013-09-30 | 2016-04-28 | Beijing Synercare Pharma Tech Co Ltd | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
WO2015075051A1 (fr) * | 2013-11-19 | 2015-05-28 | Universitaet Des Saarlandes | Inhibiteurs allostériques de protéines kinases c atypiques |
EP3082809B1 (fr) | 2013-12-20 | 2021-01-20 | Merck Sharp & Dohme Corp. | Inhibiteurs de btk |
MX2016010754A (es) | 2014-02-21 | 2017-03-03 | Principia Biopharma Inc | Sales y forma solida de un inhibidor btk. |
GB201404987D0 (en) * | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
CN105085474B (zh) * | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
EP3250567B1 (fr) | 2015-01-28 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | Dérivés de 4h-pyrrolo[3,2-c]pyridin-4-one |
GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
CN114685516A (zh) | 2015-09-16 | 2022-07-01 | 洛克索肿瘤学股份有限公司 | 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物 |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JP6728382B2 (ja) | 2015-12-16 | 2020-07-22 | エコラブ ユーエスエイ インク | 膜濾過浄化のためのペルオキシギ酸組成物 |
CA3008648C (fr) | 2015-12-16 | 2023-01-10 | Priostar Pty Ltd | Dendrimere et formulations de ceux-ci |
EP3390395B1 (fr) | 2015-12-16 | 2020-09-09 | Loxo Oncology, Inc. | Composés utilisés comme inhibiteurs de kinase |
PL3390390T3 (pl) | 2015-12-16 | 2022-01-24 | Boehringer Ingelheim International Gmbh | Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych |
WO2017106396A1 (fr) | 2015-12-16 | 2017-06-22 | Bristol-Myers Squibb Company | Hétéroarylhydroxypyrimidinones en tant qu'agonistes du récepteur apj |
-
2016
- 2016-12-16 EP EP16816363.2A patent/EP3390395B1/fr active Active
- 2016-12-16 SG SG11201805044WA patent/SG11201805044WA/en unknown
- 2016-12-16 ES ES16816363T patent/ES2828431T3/es active Active
- 2016-12-16 UA UAA202003795A patent/UA127863C2/uk unknown
- 2016-12-16 PT PT168163632T patent/PT3390395T/pt unknown
- 2016-12-16 RS RS20201291A patent/RS60982B1/sr unknown
- 2016-12-16 MA MA49809A patent/MA49809A1/fr unknown
- 2016-12-16 US US16/063,542 patent/US10695323B2/en active Active
- 2016-12-16 CO CONC2018/0006164A patent/CO2018006164A2/es unknown
- 2016-12-16 MX MX2018007267A patent/MX2018007267A/es unknown
- 2016-12-16 TN TNP/2018/000213A patent/TN2018000213A1/en unknown
- 2016-12-16 NZ NZ743553A patent/NZ743553A/en unknown
- 2016-12-16 SI SI201630920T patent/SI3390395T1/sl unknown
- 2016-12-16 DK DK16816363.2T patent/DK3390395T3/da active
- 2016-12-16 HU HUE16816363A patent/HUE051921T2/hu unknown
- 2016-12-16 PE PE2021001581A patent/PE20220507A1/es unknown
- 2016-12-16 CN CN202210311970.8A patent/CN114573510A/zh active Pending
- 2016-12-16 PE PE2018001143A patent/PE20181449A1/es unknown
- 2016-12-16 WO PCT/GB2016/053968 patent/WO2017103611A1/fr active Application Filing
- 2016-12-16 JP JP2018532035A patent/JP6731483B2/ja active Active
- 2016-12-16 IL IL285976A patent/IL285976B2/en unknown
- 2016-12-16 CN CN201680073031.7A patent/CN108473481B/zh active Active
- 2016-12-16 MD MDE20181001T patent/MD3390395T2/ro unknown
- 2016-12-16 CN CN202111022488.4A patent/CN113603645A/zh active Pending
- 2016-12-16 MA MA055064A patent/MA55064A/fr unknown
- 2016-12-16 KR KR1020187020225A patent/KR102215792B1/ko active IP Right Grant
- 2016-12-16 PE PE2021001592A patent/PE20220502A1/es unknown
- 2016-12-16 CN CN202210311995.8A patent/CN114634447A/zh active Pending
- 2016-12-16 CN CN202111022492.0A patent/CN113636978A/zh active Pending
- 2016-12-16 AU AU2016373530A patent/AU2016373530B2/en active Active
- 2016-12-16 CN CN202210310724.0A patent/CN114716381A/zh active Pending
- 2016-12-16 CN CN202210312076.2A patent/CN114621146A/zh active Pending
- 2016-12-16 EP EP20194724.9A patent/EP3782994A1/fr active Pending
- 2016-12-16 MX MX2021003478A patent/MX2021003478A/es unknown
- 2016-12-16 SG SG10202012498TA patent/SG10202012498TA/en unknown
- 2016-12-16 UA UAA201807294A patent/UA122258C2/uk unknown
- 2016-12-16 LT LTEP16816363.2T patent/LT3390395T/lt unknown
- 2016-12-16 CN CN202210312064.XA patent/CN114605327A/zh active Pending
- 2016-12-16 CA CA3008488A patent/CA3008488C/fr active Active
- 2016-12-16 CN CN202210312050.8A patent/CN114591242A/zh active Pending
- 2016-12-16 CR CR20180367A patent/CR20180367A/es unknown
- 2016-12-16 EA EA201891268A patent/EA035132B1/ru not_active IP Right Cessation
- 2016-12-16 KR KR1020217003683A patent/KR20210018530A/ko active Application Filing
-
2018
- 2018-06-10 IL IL259923A patent/IL259923B/en active IP Right Grant
- 2018-06-13 PH PH12018501268A patent/PH12018501268A1/en unknown
- 2018-06-14 CL CL2018001591A patent/CL2018001591A1/es unknown
- 2018-06-20 ZA ZA2018/04137A patent/ZA201804137B/en unknown
- 2018-08-22 US US16/109,162 patent/US10342780B2/en active Active
- 2018-08-27 US US16/113,661 patent/US10464905B2/en active Active
- 2018-11-06 HK HK18114157.0A patent/HK1263254A1/zh unknown
-
2020
- 2020-05-13 US US15/930,657 patent/US10918622B2/en active Active
- 2020-07-06 JP JP2020116636A patent/JP7086140B2/ja active Active
- 2020-07-26 IL IL276283A patent/IL276283B/en active IP Right Grant
- 2020-11-16 CY CY20201101090T patent/CY1123561T1/el unknown
- 2020-11-19 HR HRP20201835TT patent/HRP20201835T1/hr unknown
- 2020-12-15 US US17/122,103 patent/US11471441B2/en active Active
-
2021
- 2021-01-26 ZA ZA2021/00544A patent/ZA202100544B/en unknown
- 2021-02-24 IL IL281067A patent/IL281067B/en unknown
- 2021-03-23 AU AU2021201811A patent/AU2021201811B2/en active Active
- 2021-08-31 AU AU2021225162A patent/AU2021225162B2/en active Active
- 2021-08-31 AU AU2021225161A patent/AU2021225161B2/en active Active
- 2021-10-05 ZA ZA2021/07471A patent/ZA202107471B/en unknown
- 2021-10-05 ZA ZA2021/07472A patent/ZA202107472B/en unknown
- 2021-11-12 US US17/525,350 patent/US11826351B2/en active Active
-
2022
- 2022-06-07 JP JP2022092275A patent/JP7419437B2/ja active Active
-
2023
- 2023-07-31 US US18/362,249 patent/US20230372298A1/en active Pending
-
2024
- 2024-02-27 HU HUS2400003C patent/HUS2400003I1/hu unknown
- 2024-03-01 FI FIC20240004C patent/FIC20240004I1/fi unknown
- 2024-03-06 NL NL301262C patent/NL301262I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49809A1 (fr) | Composés utilisés comme inhibiteurs de kinase | |
MX2018003351A (es) | Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer. | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
EA202091709A1 (ru) | Ингибиторы днк-пк | |
MA41251B1 (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA39219A1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
MA39170B1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
MX2020002399A (es) | Inhibidores del enlace proteína-proteína de wdr5. | |
MA38284B1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
TN2018000341A1 (en) | ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF. | |
MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
EA202091708A1 (ru) | Ингибиторы днк-пк | |
PH12021550743A1 (en) | Boron containing pde4 inhibitors | |
MX2015010466A (es) | Inhibidores de tirosina cinasa de bruton. | |
MX2015010983A (es) | Inhibidores de tirosina-cinasa de bruton. | |
MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
MA39253B1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
EA202092446A1 (ru) | ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34 | |
MA42871B1 (fr) | Composés utilisés comme inhibiteurs de la tyrosine kinase de bruton (btk) | |
MA42175B1 (fr) | Dérivés de pyrazolopyrimidine comme inhibiteurs de btk pour le traitement du cancer | |
MA45367B1 (fr) | Inhibiteurs de la tyrosine kinase |